All In MedTech

Device Trial Radar · NCT03203733

Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study

Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Jun 12, 2017

Primary completion

Dec 6, 2019

Study completion Dec 31, 2019

Sponsor

Lead sponsor
Uppsala UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 29, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates, among study patients with lymphoma or myeloma undergoing autologous SCT, whether cooling oral mucosa with a cooling device compared with ice cubes/crushed ice or ice pop succeeds in reducing the degree of oral mucositis (OM) according to the Oral Mucositis Assessment Scale (OMAS) total,degree of OM according to World Health Organisation (WHO), tolerability of either cooling method. The study is also aiming to , patients subjective experience of OM, rating of general quality of life and oral pain, number of days with total parenteral nutrition (TPN), number of hospital days, total dose of opioids, and C reactive protein during time in care. Finally, the study aims to evaluate weight loss, Leukocyte particle concentration, number of days until bone marrow response, S-albumin, and body temperature.

Conditions

  • Cryotherapy Effect

Interventions

  • Cooral™Device

    An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.

  • cryotherapyOther

    Oral cooling by ice chips or crushed ice or ice pop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OM according to OMAS total during 28 days or until dischargeTime frame: 28 days or until discharge

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Rikshospitalet in Oslo

    Oslo, Norway

  • Linköping University Hospital

    Linköping, Sweden

  • Örebro University Hospital

    Örebro, Sweden

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.